Remembrance of things past — discontinuation of second-generation TKI therapy for CML
Crossref DOI link: https://doi.org/10.1038/nrclinonc.2017.11
Published Online: 2017-02-07
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hughes, Timothy P.
Ross, David M.
Text and Data Mining valid from 2017-02-07
Article History
First Online: 7 February 2017
Competing interests
: T.P.H. and D.M.R. declare that they have received research funding and honoraria from Ariad, Bristol-Myers Squibb, and Novartis.